Your browser doesn't support javascript.
loading
Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method.
Chen, D; Kapre, S; Goel, A; Suresh, K; Beri, S; Hickling, J; Jensen, J; Lal, M; Preaud, J M; Laforce, M; Kristensen, D.
Affiliation
  • Chen D; PATH, Seattle, WA 98121, USA. dchen@path.org
Vaccine ; 28(31): 5093-9, 2010 Jul 12.
Article de En | MEDLINE | ID: mdl-20478345
ABSTRACT
Thermostable vaccines promise to simplify the logistics of vaccine distribution and expand the immunization coverage. In this study, a pilot-scale spray drying process was developed and used to produce glassy state formulations of a recombinant hepatitis B (HepB) vaccine containing aluminum adjuvant and Neisseria meningitidis A (MenA) protein-polysaccharide conjugate vaccine, representing two common types of subunit vaccines in use today the spray-dried HepB vaccine formulations were stable for at least 24 months at 37 degrees C while several MenA vaccine formulations exhibited complete stability at temperatures up to 60 degrees C. This study demonstrates the feasibility of producing thermostable vaccines with advanced processing and formulation technologies.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins antibactériens / Vaccins anti-hépatite B / Dessiccation Limites: Animals Langue: En Journal: Vaccine Année: 2010 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins antibactériens / Vaccins anti-hépatite B / Dessiccation Limites: Animals Langue: En Journal: Vaccine Année: 2010 Type de document: Article Pays d'affiliation: États-Unis d'Amérique